Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan-hziy in Previously Treated Mesothelioma
NCT06477419Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2024
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in pleural mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT06477419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477419.